Cargando…
Individualized interactomes for network-based precision medicine in hypertrophic cardiomyopathy with implications for other clinical pathophenotypes
Progress in precision medicine is limited by insufficient knowledge of transcriptomic or proteomic features in involved tissues that define pathobiological differences between patients. Here, myectomy tissue from patients with obstructive hypertrophic cardiomyopathy and heart failure is analyzed usi...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7870822/ https://www.ncbi.nlm.nih.gov/pubmed/33558530 http://dx.doi.org/10.1038/s41467-021-21146-y |
_version_ | 1783648884555251712 |
---|---|
author | Maron, Bradley A. Wang, Rui-Sheng Shevtsov, Sergei Drakos, Stavros G. Arons, Elena Wever-Pinzon, Omar Huggins, Gordon S. Samokhin, Andriy O. Oldham, William M. Aguib, Yasmine Yacoub, Magdi H. Rowin, Ethan J. Maron, Barry J. Maron, Martin S. Loscalzo, Joseph |
author_facet | Maron, Bradley A. Wang, Rui-Sheng Shevtsov, Sergei Drakos, Stavros G. Arons, Elena Wever-Pinzon, Omar Huggins, Gordon S. Samokhin, Andriy O. Oldham, William M. Aguib, Yasmine Yacoub, Magdi H. Rowin, Ethan J. Maron, Barry J. Maron, Martin S. Loscalzo, Joseph |
author_sort | Maron, Bradley A. |
collection | PubMed |
description | Progress in precision medicine is limited by insufficient knowledge of transcriptomic or proteomic features in involved tissues that define pathobiological differences between patients. Here, myectomy tissue from patients with obstructive hypertrophic cardiomyopathy and heart failure is analyzed using RNA-Seq, and the results are used to develop individualized protein-protein interaction networks. From this approach, hypertrophic cardiomyopathy is distinguished from dilated cardiomyopathy based on the protein-protein interaction network pattern. Within the hypertrophic cardiomyopathy cohort, the patient-specific networks are variable in complexity, and enriched for 30 endophenotypes. The cardiac Janus kinase 2-Signal Transducer and Activator of Transcription 3-collagen 4A2 (JAK2-STAT3-COL4A2) expression profile informed by the networks was able to discriminate two hypertrophic cardiomyopathy patients with extreme fibrosis phenotypes. Patient-specific network features also associate with other important hypertrophic cardiomyopathy clinical phenotypes. These proof-of-concept findings introduce personalized protein-protein interaction networks (reticulotypes) for characterizing patient-specific pathobiology, thereby offering a direct strategy for advancing precision medicine. |
format | Online Article Text |
id | pubmed-7870822 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-78708222021-02-11 Individualized interactomes for network-based precision medicine in hypertrophic cardiomyopathy with implications for other clinical pathophenotypes Maron, Bradley A. Wang, Rui-Sheng Shevtsov, Sergei Drakos, Stavros G. Arons, Elena Wever-Pinzon, Omar Huggins, Gordon S. Samokhin, Andriy O. Oldham, William M. Aguib, Yasmine Yacoub, Magdi H. Rowin, Ethan J. Maron, Barry J. Maron, Martin S. Loscalzo, Joseph Nat Commun Article Progress in precision medicine is limited by insufficient knowledge of transcriptomic or proteomic features in involved tissues that define pathobiological differences between patients. Here, myectomy tissue from patients with obstructive hypertrophic cardiomyopathy and heart failure is analyzed using RNA-Seq, and the results are used to develop individualized protein-protein interaction networks. From this approach, hypertrophic cardiomyopathy is distinguished from dilated cardiomyopathy based on the protein-protein interaction network pattern. Within the hypertrophic cardiomyopathy cohort, the patient-specific networks are variable in complexity, and enriched for 30 endophenotypes. The cardiac Janus kinase 2-Signal Transducer and Activator of Transcription 3-collagen 4A2 (JAK2-STAT3-COL4A2) expression profile informed by the networks was able to discriminate two hypertrophic cardiomyopathy patients with extreme fibrosis phenotypes. Patient-specific network features also associate with other important hypertrophic cardiomyopathy clinical phenotypes. These proof-of-concept findings introduce personalized protein-protein interaction networks (reticulotypes) for characterizing patient-specific pathobiology, thereby offering a direct strategy for advancing precision medicine. Nature Publishing Group UK 2021-02-08 /pmc/articles/PMC7870822/ /pubmed/33558530 http://dx.doi.org/10.1038/s41467-021-21146-y Text en © This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2021, corrected publication 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Maron, Bradley A. Wang, Rui-Sheng Shevtsov, Sergei Drakos, Stavros G. Arons, Elena Wever-Pinzon, Omar Huggins, Gordon S. Samokhin, Andriy O. Oldham, William M. Aguib, Yasmine Yacoub, Magdi H. Rowin, Ethan J. Maron, Barry J. Maron, Martin S. Loscalzo, Joseph Individualized interactomes for network-based precision medicine in hypertrophic cardiomyopathy with implications for other clinical pathophenotypes |
title | Individualized interactomes for network-based precision medicine in hypertrophic cardiomyopathy with implications for other clinical pathophenotypes |
title_full | Individualized interactomes for network-based precision medicine in hypertrophic cardiomyopathy with implications for other clinical pathophenotypes |
title_fullStr | Individualized interactomes for network-based precision medicine in hypertrophic cardiomyopathy with implications for other clinical pathophenotypes |
title_full_unstemmed | Individualized interactomes for network-based precision medicine in hypertrophic cardiomyopathy with implications for other clinical pathophenotypes |
title_short | Individualized interactomes for network-based precision medicine in hypertrophic cardiomyopathy with implications for other clinical pathophenotypes |
title_sort | individualized interactomes for network-based precision medicine in hypertrophic cardiomyopathy with implications for other clinical pathophenotypes |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7870822/ https://www.ncbi.nlm.nih.gov/pubmed/33558530 http://dx.doi.org/10.1038/s41467-021-21146-y |
work_keys_str_mv | AT maronbradleya individualizedinteractomesfornetworkbasedprecisionmedicineinhypertrophiccardiomyopathywithimplicationsforotherclinicalpathophenotypes AT wangruisheng individualizedinteractomesfornetworkbasedprecisionmedicineinhypertrophiccardiomyopathywithimplicationsforotherclinicalpathophenotypes AT shevtsovsergei individualizedinteractomesfornetworkbasedprecisionmedicineinhypertrophiccardiomyopathywithimplicationsforotherclinicalpathophenotypes AT drakosstavrosg individualizedinteractomesfornetworkbasedprecisionmedicineinhypertrophiccardiomyopathywithimplicationsforotherclinicalpathophenotypes AT aronselena individualizedinteractomesfornetworkbasedprecisionmedicineinhypertrophiccardiomyopathywithimplicationsforotherclinicalpathophenotypes AT weverpinzonomar individualizedinteractomesfornetworkbasedprecisionmedicineinhypertrophiccardiomyopathywithimplicationsforotherclinicalpathophenotypes AT hugginsgordons individualizedinteractomesfornetworkbasedprecisionmedicineinhypertrophiccardiomyopathywithimplicationsforotherclinicalpathophenotypes AT samokhinandriyo individualizedinteractomesfornetworkbasedprecisionmedicineinhypertrophiccardiomyopathywithimplicationsforotherclinicalpathophenotypes AT oldhamwilliamm individualizedinteractomesfornetworkbasedprecisionmedicineinhypertrophiccardiomyopathywithimplicationsforotherclinicalpathophenotypes AT aguibyasmine individualizedinteractomesfornetworkbasedprecisionmedicineinhypertrophiccardiomyopathywithimplicationsforotherclinicalpathophenotypes AT yacoubmagdih individualizedinteractomesfornetworkbasedprecisionmedicineinhypertrophiccardiomyopathywithimplicationsforotherclinicalpathophenotypes AT rowinethanj individualizedinteractomesfornetworkbasedprecisionmedicineinhypertrophiccardiomyopathywithimplicationsforotherclinicalpathophenotypes AT maronbarryj individualizedinteractomesfornetworkbasedprecisionmedicineinhypertrophiccardiomyopathywithimplicationsforotherclinicalpathophenotypes AT maronmartins individualizedinteractomesfornetworkbasedprecisionmedicineinhypertrophiccardiomyopathywithimplicationsforotherclinicalpathophenotypes AT loscalzojoseph individualizedinteractomesfornetworkbasedprecisionmedicineinhypertrophiccardiomyopathywithimplicationsforotherclinicalpathophenotypes |